Home
overview

Building on successive sell out conferences within the pharmaceutical industry, SMi have produced a unique conference which deals exclusively with the crucial issues surrounding new developments in CNS drugs.

The CNS market is expanding rapidly; the WHO approximate 5.5% of the global population suffers from anxiety disorders at least once during life and there will be an estimated 10.3 million patients with Alzheimer’s and Parkinson’s disease. Finding new therapies for these and other CNS disorders and determining the biological mechanisms of seriously debilitating forms of psychiatric illness is of great interest to the pharmaceutical industry.

This conference will encompass issues in clinical development of centrally acting compounds, with expert presentations from a superb panel speakers at the forefront of CNS research. The topics will cover innovation in preclinical and clinical research across a range of disease indications including; Neurodegenerative disease; Bipolar disorders; and Schizophrenia.

Conference programme

8:30 Registration and Coffee

9:00 Chairman’s Opening Remarks

John Edmunds

John Edmunds, Director, Stevenden Healthcare

9:10 STRATEGIC DEVELOPMENT OF CNS DRUGS

Joanne Bell

Joanne Bell, VP CNS Product Development, PPD Pharmaco

  • Designing appropriate trials for the drugs
  • Issues of clinical trial design
  • Designing Proof of Concept trials
  • Possibilities of the use of ’neurogenomics’ in speeding clinical development
  • The range of CNS indications - developing expertise across differing disease
  • How to maximise the whole development process
  • 9:40 STROKE DEVELOPMENT

    James Vornov

    James Vornov, Associate Director, Clinical Research

  • Why temporary occlusion models make it so easy to treat strokes in rats
  • Why clinical medicine makes it so hard to treat strokes in man
  • Why combination therapy may be needed- the issues of reperfusion and white matter protection
  • How biomarkers and surrogate endpoints may help to find effective doses
  • Agents that are better tolerated and allow therapeutic levels in patients
  • Using prophylactic therapy to avoid the difficulties of a brief therapeutic window
  • 10:20 TREATMENT OF BRAIN DISORDERS

    Dr John Sinden

    Dr John Sinden, Chief Scientific Officer, ReNeuron

  • Injury to or disease of the brain can lead to mental, physical or behavioural disability
  • Ethical and practical considerations - Alternative approaches to therapy
  • Implantation of neuroepithelial stem cells into the damaged brain
  • Clinical studies and expansion of research programmes to investigate a wide range of damage and disease
  • Creating a viable alternative for future treatments
  • 11:00 Morning Coffee

    11:20 NEUROSCIENCE, ENDOCRINOLOGY AND IMMUNOLOGY

    Alan Foster

    Alan Foster, Director of Neuroscience, Neurocrine Biosciences

  • Development of novel therapeutics for neuro-psychiatric, -inflammatory and degenerative disease and disorders
  • A unique biological understanding of the molecular interaction between the CNS, immune and endocrine systems
  • Cancer of the brain - necrosis using IL-4 fusion toxin
  • The benefits of multinational trials to confirm initial data - establishing the therapeutic potential of the compound
  • Collaborative partnerships enhancing the advancement of CNS products
  • Developing clinical research programs and employing advanced technologies to discover and design new small molecule therapies
  • 12:00 PROPRIETARY THERAPEUTICS IN CNS DISORDERS

    Louis R Bucalo

    Louis R Bucalo, CEO and President, Titan Pharmaceuticals

  • The development of novel biopharmaceutical products in the CNS field
  • Antipsychotic agent - Iloperidone
  • Developing worldwide multicentre clinical trials
  • Cell therapy for neurodegenerative disease - Parkinson’s Disease
  • Moving on from pilot studies
  • Creating a successful pipeline of products across a range of indications
  • 12:40 Lunch

    14:00 NEURODEGENERATIVE DISEASE

    Dr Jeffrey Waught

    Dr Jeffrey Waught, President of Research, Cephalon

  • Discover, develop and market innovative products to treat neurological disorders
  • Core technologies in CNS clinical research
  • Neurotrophic recombinant proteins
  • Protease Inhibitors
  • Signal transduction modulation and gene transcription regulators
  • Strategies to manage the risks inherent in drug development
  • 14:40 EPILEPSY AND ANTICONVULSION

    Michael D Coffee

    Michael D Coffee, President and CEO, Athena Neurosciences

  • In the US alone - 2.5 million patients, subsets of patients with acute episodic epilepsy
  • Need for fast acting preventative therapies
  • Diastat - antiseizure product approval
  • Maintaining and marketing a product portfolio in CNS/epilepsy therapy
  • Building the epilepsy franchise
  • 15:20 Afternoon Tea

    15:40 INNOVATIONS IN NEUROSCIENCE

    Nigel Capps

    Nigel Capps, Commercial Manager, Cerebrus Research

  • Discovering novel drug candidates for CNS disorders
  • The benefit of focused development pipelines - areas of clinical need
  • Integrating medicinal chemistry with in vitro and in vivo biological models for the rapid assessment of NCEs
  • Benefits of collaboration with centres of excellence
  • Complementing internal research programmes and partnering lead research programmes
  • 16:20 TREATMENT OF NEUROPATHIC PAIN AND AIDS RELATED DEMENTIA

    Lisa U. Carr

    Lisa U. Carr, Vice President, Medical Affairs, Neurobiological Technologies

  • Memantine - restore function of impaired neurons by NMDA receptor modulation
  • Neuropathic pain
  • AIDS related dementia - neurological complications arise even with optimal retroviral therapies
  • Clinical trials for use of Memantine in AIDS dementia and neuropathic pain
  • Developing CNS targeted drugs for unmet disease
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman’s Opening Remarks

    John Edmunds

    John Edmunds, Director, Stevenden Healthcare

    9:10 THE CENTRAL NERVOUS SYSTEM AND STROKE

    Carl M. Cohen

    Carl M. Cohen, Vice President, Research, Creative Biomolecules

  • Medical emergency for which there is limited available treatment
  • New possibilities for design of stroke recovery trials
  • Presenting a new approach to stroke - OP-1
  • Enhancing the natural regenerative processes to compensate for damage
  • Extending the intervention window: hours to days
  • Stroke therapy available to the majority of victims
  • 9:40 NEW DIAGNOSTICS FOR PARKINSON’S DISEASE

    Marc Lanser

    Marc Lanser, Chief Scientific Officer, Boston Life Sciences International

  • Need for early detection and diagnosis of Parkinson’s
  • Altropane: Clinical trial results
  • Development of a second generation technetium product
  • 10:20 ACTIVATION OF CNS AXONAL GROWTH

    Dr. Larry Benowitz

    Dr. Larry Benowitz, Associate Professor, Neuroscience, Harvard Medical School and Director, Laboratory for Neuroscience, Children’s Hospital, Boston, MA

  • Mechanisms controlling axonal growth in the CNS
  • Lead potential therapeutic compounds to regenerate CNS axons
  • Results of in vivo studies
  • Implications for treatment of acute and chronic CNS disorders
  • 11:00 Morning Coffee

    11:20 PROMISING NEW CLASSES OF DRUGS

    Paul Averback

    Paul Averback, President and CEO, Nymox Pharmaceuticals

  • Central destruction of the brain by spheron action
  • Spherons are directly linked to amyloid plaque formation in the human brain
  • Spherons and plaques are co-localised within the brain and contain similar key molecules
  • From hypothesis to treatment - oral delivery of drugs that cross the BBB
  • Human clinical trials for a new drug range
  • 12:00 MEMORY AND COGNITION

    Vincent F Simmon

    Vincent F Simmon, President & CEO, Cortex

  • Using and developing AMPA receptor-modulating compounds
  • Proprietary pharmaceuticals which act at brain cell connections to increase strength of signal
  • The benefits of amplifying glutamate based nerve communication
  • Developing Ampakine compounds which target only nerve cell connections in the brain
  • Patent coverage on novel CNS compounds, providing a window for a strong patent portfolio
  • 12:40 Lunch

    14:00 NEW DRUG DEVELOPMENT TOOLS

    Malcolm Cooper

    Malcolm Cooper, Chairman and Senior Scientist, MIICRO

  • Inherently difficult area of research - increased risks of failure
  • Lack of reliable animal models, high placebo effects, patient heterogeneity
  • Determining appropriate dose range for new drugs
  • Using metabolic neuroimaging for dose evaluation
  • Positron Emission Tomography (PET) analyses - how drugs alter brain activity
  • Allowing rational trial design and lower failure rates due to inappropriate dose selection
  • 14:40 TREATING ANXIETY

    Peter Moldt

    Peter Moldt, Drug Development, NeuroSearch

  • GABA modulators in CNS indications
  • NS2710 for the treatment of anxiety
  • Preclinical data suggesting superior separation between efficacy and side effects
  • Collaboration to develop and commercialise new CNS products
  • Securing an accelerated path to the market for products
  • Further development work and future portfolio building
  • 15:20 Afternoon Tea

    15:40 BRAIN DELIVERY TECHNOLOGY

    Michael Kaczorek

    Michael Kaczorek, President and CEO, Synt:em

  • Problems of safe and efficient crossing of complex membrane barriers
  • Developing non-invasive techniques for delivering drugs directly through the blood-brain barrier
  • Pep:trans technology based on peptide derived vectors that are able to cross biological membranes
  • Vectors aimed at diseases of the CNS - computational drug delivery defining drug candidates
  • Expanding effective therapies for CNS disorders
  • 16:20 PROPRIETARY DRUG DISCOVERY IN CNS DISEASE

    Dr Jeffrey F McKelvy

    Dr Jeffrey F McKelvy, Chief Scientific Officer, SIBIA Neurosciences

  • Using advanced drug discovery technologies to identify compounds for pre-clinical development
  • Benefits of targeting a large range of disorders
  • Identifying molecular targets and corresponding assays for high throughput screening and identification of lead molecules
  • Collaborations within the pharma and biotech industries for further development and commercialisation of drug candidates
  • Future programs and areas for drug development - meeting unmet needs
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    Thistle Westminster

    Buckingham Palace Road
    London SW1W 0QT
    United Kingdom

    Thistle Westminster

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.